News

We recently published 10 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks that on Jim Cramer’s radar. Pharma giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Over the past couple of months, Cramer has turned optimistic about the company. Some […]

Pennsylvania jury awards damages in a talc lawsuit involving Johnson & Johnson products. Researchers identify a mechanism behind rare blood clots associated with the company’s COVID vaccine. Johnson & Johnson reports positive pilot phase safety and effectiveness data for its OMNYPULSE and VARIPULSE catheter platforms. Johnson & Johnson (NYSE: JNJ) sits at the center of several high impact developments that span litigation, vaccine safety research, and new medical device data. The stock last...

By Diana Novak Jones Feb 13 (Reuters) - A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to

Johnson & Johnson (NYSE:JNJ) is among the most profitable mega cap stocks to buy. On February 6, Johnson & Johnson (NYSE:JNJ) disclosed 12-month pilot-phase data from the OMNY-AF study, which examined the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib). Announced during the 31st Annual AF Symposium in Boston, the results […]

Johnson & Johnson (NYSE:JNJ) is one of the best medical research stocks to buy according to hedge funds. Johnson & Johnson (NYSE:JNJ) announced 12-month pilot-phase data from the OMNY-AF study on February 6 at the 31st Annual AF Symposium in Boston, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation. It […]

Johnson & Johnson (NYSE:JNJ) presented pilot-phase data for its OMNYPULSE and VARIPULSE atrial fibrillation platforms at the 31st Annual AF Symposium. The company reported industry first safety and effectiveness outcomes for these pulsed field ablation technologies. The data suggest potential for redefining minimally invasive electrophysiology procedures in cardiac care. For you as an investor, this update sits inside Johnson & Johnson’s broader medical technology push, where cardiac care...

This reliable dividend payer may be just what the doctor ordered.

What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...